GlassScriptPhysician profile
Rakesh Shreedhar
NPI 1366403339
$2,812.24
in general payments reported to CMS, 2019-2025
17 companies · $399 in 2025
The $399 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $926 · 2020: $763 · 2021: $473 · 2023: $125 · 2024: $126 · 2025: $399.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $650.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $650.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,233.73 | 2019-2023 | Tezspire |
| Intuitive Surgical, INC. | $439.45 | 2019-2020 | |
| Allergan, INC. | $140.21 | 2019-2020 | |
| Boston Scientific Corporation | $129.60 | 2025 | Watchman Flx |
| Seapearl East, INC | $126.27 | 2024 | |
| Novo Nordisk INC | $125.00 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.00 | 2019 | |
| Amarin Pharma, INC. | $124.97 | 2019 | |
| Davol INC. | $119.87 | 2025 | Phasix Mesh |
| Corcept Therapeutics | $78.36 | 2025 | Korlym |
| Abbott Laboratories | $71.16 | 2025 | Eterna |
| Portola Pharmaceuticals, LLC | $19.30 | 2019 | |
| Mallinckrodt Enterprises LLC | $18.43 | 2019 | |
| Pfizer INC. | $16.42 | 2019 | |
| Acell, INC. | $15.56 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $14.65 | 2019 | |
| Covidien LP | $14.26 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rakesh Shreedhar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.